BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 31595974)

  • 1. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
    Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
    J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo.
    Nagare RP; Sneha S; Krishnapriya S; Ramachandran B; Murhekar K; Vasudevan S; Shabna A; Ganesan TS
    Exp Cell Res; 2020 Jul; 392(1):112009. PubMed ID: 32305326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells.
    Shanmugam G; Mohan A; Kumari K; Louis JM; Soumya Krishnan U; Balagopal PG; George NA; Sebastian P; Maliekal TT
    Exp Cell Res; 2019 Oct; 383(2):111551. PubMed ID: 31401066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is sphere assay useful for the identification of cancer initiating cells of the ovary?
    Martínez-Serrano MJ; Caballero-Baños M; Vilella R; Vidal L; Pahisa J; Martínez-Roman S
    Int J Gynecol Cancer; 2015 Jan; 25(1):12-7. PubMed ID: 25365589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAMPT Inhibition Suppresses Cancer Stem-like Cells Associated with Therapy-Induced Senescence in Ovarian Cancer.
    Nacarelli T; Fukumoto T; Zundell JA; Fatkhutdinov N; Jean S; Cadungog MG; Borowsky ME; Zhang R
    Cancer Res; 2020 Feb; 80(4):890-900. PubMed ID: 31857293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.
    Huddle BC; Grimley E; Buchman CD; Chtcherbinine M; Debnath B; Mehta P; Yang K; Morgan CA; Li S; Felton J; Sun D; Mehta G; Neamati N; Buckanovich RJ; Hurley TD; Larsen SD
    J Med Chem; 2018 Oct; 61(19):8754-8773. PubMed ID: 30221940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
    Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
    Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.
    Fischer AK; Pham DL; Bösmüller H; Lengerke C; Wagner P; Bachmann C; Beschorner C; Perner S; Kommoss S; Fend F; Staebler A
    Virchows Arch; 2019 Oct; 475(4):479-488. PubMed ID: 31451895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression.
    Namekawa T; Ikeda K; Horie-Inoue K; Suzuki T; Okamoto K; Ichikawa T; Yano A; Kawakami S; Inoue S
    Int J Cancer; 2020 Feb; 146(4):1099-1113. PubMed ID: 31187490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
    Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
    Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.
    Huang TT; Brill E; Nair JR; Zhang X; Wilson KM; Chen L; Thomas CJ; Lee JM
    Cancer Res; 2020 Dec; 80(23):5380-5392. PubMed ID: 32998994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
    Liao J; Qian F; Tchabo N; Mhawech-Fauceglia P; Beck A; Qian Z; Wang X; Huss WJ; Lele SB; Morrison CD; Odunsi K
    PLoS One; 2014; 9(1):e84941. PubMed ID: 24409314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.
    Yoshino J; Akiyama Y; Shimada S; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Carcinogenesis; 2020 Jul; 41(6):734-742. PubMed ID: 31665232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells.
    Kim DK; Seo EJ; Choi EJ; Lee SI; Kwon YW; Jang IH; Kim SC; Kim KH; Suh DS; Seong-Jang K; Lee SC; Kim JH
    Exp Mol Med; 2016 Aug; 48(8):e255. PubMed ID: 27561949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.